2. Antibody-drug Conjugate/ADC Related Cytoskeleton Cell Cycle/DNA Damage
  3. Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin
  4. Cofetuzumab pelidotin

Cofetuzumab pelidotin  (Synonyms: PF-06647020; ABBV-647; h6M24-vc0101)

目录号: HY-P99829 纯度: 99.67%
COA

摩尔计算器

Cofetuzumab pelidotin (PF-06647020) 是一种靶向 PTK7 的 ADC，包含人源化抗 PTK7 mAb (hu6M024；IgG1)，通过可裂解的缬氨酸-瓜氨酸 (vc) 的 linker 与 auristatin 微管抑制剂 Auristatin-0101 (Aur0101；HY-12522) 连接。Cofetuzumab pelidotin 的 DAR 为 4。Cofetuzumab pelidotin 与细胞表面 PTK7 结合的 EC50 为 1153 pM (通过流式细胞术检测)。Cofetuzumab pelidotin 具有用于实体瘤研究的潜力。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Cofetuzumab pelidotin Chemical Structure

Cofetuzumab pelidotin Chemical Structure

CAS No. : 1869937-48-3

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
1 mg ￥6500
In-stock
5 mg   询价  
10 mg   询价  

* Please select Quantity before adding items.

Customer Review

Cofetuzumab pelidotin 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC50 of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research[1][2][3].

体外研究
(In Vitro)

Cofetuzumab pelidotin (PF-06647020) 对表达 PTK7 的癌细胞系 H446、H661 和 OVCAR3 具有体外细胞毒性作用，EC50 值分别为 7.6、27.5 和 105 ng/mL[1]。
Cofetuzumab pelidotin (持续 6 天)在一组癌细胞系 (A549、MDA-MB-468、KYSE-150、SKOV-3、PC9、NCI-H1975) 细胞中显示出高效力和 PTK7 特异性细胞毒性，IC50 为 0-1100 nM[2]。
Cofetuzumab pelidotin 稳定性较差，T1/2 不足 3 天[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cofetuzumab pelidotin 相关抗体:
体内研究
(In Vivo)

Cofetuzumab pelidotin (PF-06647020；3 mg/kg；腹腔注射，每周两次，持续四个周期) 对 NSCLC、OVCA 和 TNBC 的 PDX 小鼠模型产生显着抗肿瘤作用[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 6- to 10-week-old NOD scid mice with NSCLC, OVCA and TNBC cells[1]
Dosage: 3 mg/kg
Administration: Intraperitoneal injection twice a week for four cycles
Result: Induced striking in vivo anti-tumor effects on a subset of patient–derived xenografts (PDXs) derived from NSCLC, OVCA and TNBC.
CAS 号
性状

液体

颜色

Colorless to light yellow

运输条件

Shipping with dry ice.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

Cofetuzumab pelidotin 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Cofetuzumab pelidotin1869937-48-3PF-06647020 ABBV-647 h6M24-vc0101PF06647020PF 06647020ABBV647ABBV 647ABBV-647Antibody-Drug Conjugates (ADCs)Microtubule/TubulinAntibody-Drug ConjugatesPTK7hu6M024IgG1auristatinvaline-citrullinesolid tumorInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Cofetuzumab pelidotin
目录号：
HY-P99829
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z